Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C

Table 5 Patients with adverse events

Adverse event	n (%) of patients
	Genotype 1	Genotype 31	Genotype 4
	(n = 27)	(n = 56)	(n = 17)
Injection-site reactions	9 (33.3)	16 (28.6)	7 (41.2)
Flu-like symptoms	24 (88.8)	49 (87.5)	14 (82.3)
Tiredness	4 (14.8)	5 (8.9)	2 (11.7)
Weight loss	1 (3.7)	3 (5.4)	1 (5.8)
Chest discomfort	1 (3.7)	2 (3.6)	2 (11.7)
Arthralgia	3 (11.1)	0 (0)	1 (5.8)
Alopecia	2 (7.4)	10 (17.9)	3 (17.6)
Anorexia	2 (7.4)	7 (12.5)	3 (17.6)
Nausea	3 (11.1)	8 (14.3)	3 (17.6)
Vomiting	2 (7.4)	3 (5.4)	0
Dyspepsia	1 (3.7)	3 (5.4)	2 (11.7)
Gastritis	1 (3.7)	0 (0)	0
Mucous stool	1 (3.7)	0 (0)	0
Diarrhea	1 (3.7)	4 (7.1)	1 (5.8)
Melena	1 (3.7)	6 (10.7)	0
Ascites	1 (3.7)	0 (0)	0
Thrombocytopenia	2 (7.4)	5 (8.9)	1 (5.8)
Anemia	9 (33.3)	13 (23.2)	6 (35.3)
Neutropenia	12 (44.4)	15 (26.8)	8 (47.0)
Anxiety	1 (3.7)	3 (5.4)	1 (5.8)
Depression	2 (7.4)	4 (7.1)	3 (17.6)
Insomnia	1 (3.7)	1 (1.8)	2 (11.7)
Hypothyroidism	2 (7.4)	2 (3.6)	2 (11.7)
Giddiness	1 (3.7)	1 (1.8)	2 (11.7)
Dry throat	1 (3.7)	1 (1.8)	0 (0)
Cough	2 (7.4)	2 (3.6)	2 (11.7)
Sinusitis	1 (3.7)	0 (0)	0 (0)
Bleeding gums	2 (7.4)	1 (1.8)	0 (0)
Palpitation	1 (3.7)	0 (0)	0 (0)
Pruritus	0 (0)	0 (0)	1 (5.8)
Yellow-colored sputum	0 (0)	0 (0)	1 (5.8)
Urinary tract infection	1 (3.7)	0 (0)	0 (0)
Death	0 (0)	1 (1.8)	0 (0)
No. of patients reporting AEs	24 (88.8)	49 (87.5)	14 (82.3)
Discontinued due to SAEs	0 (0)	2 (3.6)	0 (0)
Temporary discontinuation of therapy	4 (14.8)	3 (5.4)	3 (17.6)
Temporary dose reduction	11 (40.7)	16 (29.6)	5 (29.4)

¹Includes one patient with genotype 2. SAE: Serious adverse event.